Endpoints Webinars

Life sciences marketers work with long sales cycles and products that require market education — which make webinars one of the most essential tools in the biopharma demand generation toolbox.

Endpoints webinars are a turn-key solution — let us handle the audience generation, marketing, and tech.

Upcoming Webinars

Venture capital velocity: What’s driving renewed momentum in biotech

Case study: Marketing to HCPs using data-based omnichannel segmentation

Utilizing novel icIEF fractionation and mass spec for the charge characterization of biotherapeutics

past Webinars

How real-world research can streamline post-marketing studies in oncology

Enabling Adaptive Clinical Trials through Integrated Development and Manufacturing Solutions

Enhance your long-term cell & gene therapy success with pDNA manufacturing solutions

Applying Real-World Data: Use cases and FDA guidance

Navigating Policy, Funding, CMC and Regulatory Dynamics for Successful Orphan Drug Development

Latest Data: How ctDNA can transform interventional trial design for GI cancers

Leveraging large-scale mRNA biology data to advance disease understanding

3 things every life sciences company should know before leveraging AI to generate real-world evidence

Navigating the clinical AI landscape & charting your path to precision medicine

The top 100 venture investors in biotech: Who’s in, what’s out

7 questions gene therapy developers should ask their CDMO (and what they will ask you!)

Untapped potential: Integrating MRD testing to track diffuse large B-cell lymphoma in clinical trials and in the clinic

Post-SABCS summary & year in review: ctDNA in drug development for breast cancer

Advertising with Endpoints: Our publisher's take on success stories of 2023

Biopharma communications: Audience engagement strategies to rebuild confidence

Advancing Non-Small Cell Lung Cancer drug discovery and treatment with clinicogenomics

The Endpoints 100 survey: What are industry execs saying about 2024?

CRISPR genome editing solutions from discovery to clinic

High Lp(a): The unmet need and value of an expansive drug development landscape

Data-based strategies for successful digital health technology (DHT) clinical trials

State of the union for advanced therapies

Can oncolytic viruses make a comeback?

Data: The unsung hero of AI

Scalable data strategies for scientific AI-enabled breakthroughs

Oncology case studies: How two life sciences companies applied real-world evidence to drive innovation

Unlocking insight from health data with healthcare-specific AI that thinks like a physician

Actionable data: Challenges, solutions and case studies across pharma research

Raising capital: A new playbook for a new era in biotech

Evolving DNA-Encoded Library (DEL) technology to meet drug discovery needs

A roadmap to earlier efficacy predictors and drivers in cell therapy development

Re-activating the immune system against cancer: The next I-O revolution

Harnessing cell power: Targeted protein degraders’ potential in combating disease

Targeted Protein Degraders – Key Strategies to Maximize VC Funding and Clinical Success

De-risking clinical development and driving therapeutic innovation: The power of RWD from EHRs

Drug research institutes put dealmaking on the front burner

Rise of mRNA manufacturing

Cryo-electron microscopy is revolutionizing rational drug discovery pipelines

The future of cell therapy manufacturing has arrived

How to plan for fill finish manufacturing success

Applying novel pairing technology for more diverse antibody discovery

How immune repertoire sequencing is addressing unmet needs in multiple sclerosis drug development

Advancing health equity in clinical trials by addressing the financial burden

Clinical trials in China: unlocking the potential of advanced therapies

The catastrophe of traditional statistical learning

Alzheimer’s disease: Using deep human biology learning to guide next-generation treatments

Harnessing the power of antigen specific T-cell responses to improve vaccine development

The future of cell therapy development and delivery

How biophysics can change the receive characteristics of tumors

Pharma can target ultra-rare conditions — the next step is financing them

Post-ASCO Summary: ctDNA as a patient selection and early efficacy marker in drug development

Accelerating all phases of the immuno-oncology drug development pipeline via immunosequencing

Transforming clinical research: Scaling real-world data across diseases with expert-led AI

Maximizing efficiency in your next state-of-the-art facility build

Life sciences dealmaking faces more antitrust scrutiny

Blood cancer breakthroughs: what’s next for underserved markets

The connected lab: maximizing the intersection of science and data

How to assess the quality of AI output when structuring unstructured medical data

ASCO '23 Preview: Key trials with high clinical and commercial impact

Targeted Protein Degraders: Through the Lens of the Innovation, Developability, and CMC Challenges

The AI drug-discovery revolution: How NYC is prepared to lead

Hungry for knowledge? Set the table for HCP and patient engagement

When to call it quits: VCs making tough decisions in a tough market

Exposing hidden targets within the mRNA regulation space

A novel 3D approach to imaging gene therapy expression and vector biodistribution

CAR-T beyond cancer

Beyond AAV: Prepare for the next generation of advanced therapy delivery

FDA Inspection Readiness: Before, During, and After

Big cardio is back in focus

Pairing quality genomic data with longitudinal patient records

New data: ctDNA as a prognostic and predictive biomarker in early-stage gastrointestinal cancers

Keeping pace with the evolving global landscape in vaccine development

Let’s talk: Moving CGTx clinical development forward in 2023

Beyond vaccines: Where mRNA technology goes next

Biopharma smart factories: Achieving next-generation performance

The top 100 biotech VCs: Who’s staying at the table and what do they want now?

Small molecule orphan drugs: Status quo, challenges, and perspectives

Expediting drug product development and commercialization in global markets with global filing strategies

Three data resolutions every biotech needs to set — and stick to — in 2023

Decentralized trial solutions for complex clinical trials

Endpoints' most popular content this year – an exclusive view for marketers

New data: Predict breast cancer treatment response and recurrence risk with ctDNA

Is Alzheimer’s R&D finally moving past the crossroads?

Digital therapeutics: Software is now entering mainstream therapeutic care

State of the union for advanced medicines

Why oncology needs more than MRD

Weird and wonderful case studies: Real-world solutions for unexpected bioanalytical challenges

How will AI transform the future of medicine?

Patient need for novel therapies in ROS1 fusion-positive non-small cell lung cancer

Navigating industry challenges to drive sustainable Plasmid DNA strategies

The vaccine R&D revolution goes global

Overcoming manufacturing challenges for advanced medicines

Lessons learned in bringing novel options for rare liver diseases to patients and families

Making the case for digital transformation in biotech R&D

Gene therapy roundup—what to know now from the lab to the FDA

Accelerate drug development with clinicogenomic RWE

The Biotech landscape: Market trends, priorities, predictions, and pathways to FDA approval

Advanced dosage forms: Tackling drug delivery challenges & addressing patient needs

The clinical trial recruitment crisis hits home

The evaluation of pan-cancer and oncoReveal™ CDx panels to support localized NGS testing

Project Optimus: Early-stage haste can lead to waste

A journey without a map: lessons in building an oncology powerhouse where innovation thrives

Changing the paradigm for colorectal cancer: Clinical practice & drug development

A crisis in rare disease: How the current investment landscape is stifling rare disease development

Why can’t we agree on how to define digital twins in healthcare?

Hit discovery with self-service DNA-encoded Libraries

Parkinson’s R&D: Have we finally reached a turning point?

Integrated clinical development and supply: Breaking down the early-development journey of a small molecule

Identify and quantify point mutations in circulating tumour DNA: The ddPCR approach™

Planning for CGT commercialization: It starts sooner than you think

Developing optimal biomarkers for cancer immunotherapy

Biology's modern LIMS for labs of the future

Pain R&D: Plenty of pain to go around, but who’s making gains?

Advanced plasmid technology: improving safety and performance​

How could an open access DNA-encoded library benefit your research?

New data: How ctDNA is evolving oncology patient management and drug development

Evolution of cell & gene therapy in China: the case for universal CAR-T

Public markets' impact on manufacturing advanced therapies

Mission critical: Cybersecurity

New biomarkers are remapping the world of cancer studies

Double your development speed: a new approach to viral vector design

Accelerating first-in-class and best-in-class programs using a large-scale digital chemistry strategy

Rethinking market access: Delivering on the promise of therapeutic innovation

Applying machine learning to increase clinical trial efficiency: a regulatory journey

Building a digital foundation for patient-centric trials

Data’s influence early in the commercialization process

How to create a stand-out customer experience for cell and gene therapies

Solving complex immunogenicity challenges

R&D changemakers: Building Resilience’s digital infrastructure for a modern R&D team

How can real-world clinico-genomics data optimize drug development?

The R&D challenge: What are the best practices in drug development today?

The role of Parkinson’s Disease biomarkers in drug development clinical trials

Metabolomics in drug discovery: The missing piece for multi-omics data

Making innovation matter by ensuring access to cancer care

The new psychedelic age in biotech

The phase 1 trial setup toolbox

Planning for the commercialization of advanced therapies

AI faces its moment of truth

Diagnostics from digital pathology: an AI solution to accelerate precision medicine

Different approaches to process development and manufacturing in gene therapy

How can biopharma deliver on the promise of precision medicine?

The pillars of research in 2035

The top 100 VCs in biotech 2022

Did you know Australia does toxicology?

Navigating your biopharma drug candidate through early and mid-stage clinical trials

The checkpoint debate is about to get real

Ensuring sample integrity from collection to analysis

CQV strategies that increase speed-to-market for gene therapy

Enterprise R&D technology adoption case study: Genentech

Checkpoint inhibitors: the gut microbiome’s role in anti-tumor response

Using external data to accelerate randomized controlled trials without introducing bias

State of the union for advanced medicines

CQV strategies to optimize cell therapy manufacturing

Innovations in clinical trial design with ctDNA MRD

Developing the next big vaccine technologies

Running decentralized trials at scale

mHealth innovation: identifying the best patient-centered technology for your trial needs

How biotechs have found success with University of Florida technologies

Changing the game: an examination of cutting-edge novel oncology screening tools

Scaling up a gene therapy manufacturing facility

A new class of startups is scouting for deals - on both sides of the Pacific

DEL like never before - 4th generation of DEL kits

Driving efficiencies through virtual trial solutions in Asia Pacific

After a decade of consolidation, who rules the CRO roost?

Concept to dosing: Challenges in new orphan drugs

Is the AI revolution empowering the scientist?

How Regeneron scaled its cloud to support millions of samples a year

Can changing one step change everything? Replacing your polishing step with a single-use solution

Pricing strategies for advanced therapies

HQ plasmid DNA: a case for phase dependent approaches to manufacturing

Non-clinical and clinical pathways for rapid vaccine development in Australia

Leading with data: tumor-informed ctDNA testing across cancer types

After the pandemic, antibody R&D remains key

Strategies for building a cell therapy manufacturing facility

The neurosciences comeback: After a lengthy chill, Big Pharma is warming back up to neuro

Recent key advances in autologous stem cell-derived therapies

Expedited clinical development strategies for China

Protein degradation: Looking back and moving forward

Enrolling a global study ahead of schedule (during a pandemic)

The big platform plays have been in vogue. But for how long?

Essential strategies for gene therapy - from assay development to CDx commercialization

Innovation in drug product manufacturing: how do we bring new therapies to patients faster?

Life science SPACs – the future of IPOs/crossover investing? A look at 2021/2022

Kantar Health on the most impactful trials at ASCO

Reinventing Harvest Technology: Single-stage chromatography clarification for recombinant protein therapeutic manufacturing

Reengineering CAR-T for solid tumors

Informed by the tumor: new data on the power of a personalized ctDNA assay

Deconvoluting inflammation and immunology for clinical trials

How scalable and intensified is your CAR-T process?

Improving endpoint selection in Alzheimer’s disease trials

Are we ready for the medicines of tomorrow? Creating the infrastructure for the era of genomic medicine

Plasmid DNA Insights: Expanded focus on CMC in gene & cell therapy development

Developing and using digital biomarkers

Transformative approaches to clinical development: Scaling adoption across the industry

Realizing the full potential of clinicogenomics

Hot topics in Immunoassay Bioanalysis - navigating the immunogenicity and biomarker requirements for clinical trials

The Great Debate: Internal vs. external manufacturing for advanced therapies

Predict placebo response using patient psychology to increase trial power

Can sponsors collect data in Expanded Access (EAPs) and Named Patient Programs (NPPs)?

Clinical trial diversity in the Covid-19 era — are we seeing a paradigm shift?

The benefits of running clinical trials in China

Where does your organization sit on the omnichannel maturity curve?

Flattening the 'valley of death:' New tools in the hunt for better preclinical R&D

Repurposing drugs for new indications: benefits and challenges

Leveraging APAC partnerships to de-risk clinical trials

Patient-First R&D: Why the patient experience should be at the center of clinical trial design

Navigating the path to the clinic and beyond for gene therapies

Beyond AAV 1.0

Enabling multidimensional tumor immunogenomics for advancing biomarker discovery

Breakthrough Technologies to Accelerate Biologic Drug Discovery, Cell Line Development and Biomanufacturability

How the World’s First Biolabs Client Portal GALEXI™ Delivers Real-Time Study Management for Biotechs

The Patient Voice in Rare Disease Research

Redefining conditioning for a new era of gene therapy

DEL Kits Special Event: A New Method of Hit Discovery

Optimizing Direct-to-Patient Clinical Supply for Decentralized Clinical Trials

Amgen’s BiTE® Platform and the Next Frontier in Immuno-Oncology

Innovation in Clinical Research: AI-based Drug Development Tools and the Regulatory Landscape

R&D in an age of Covid-19: Tackling the key issues around starting, or restarting an early-stage study

Solving hard go-to-market challenges

New Platform for Target-to-Hit: From Fragment Screen to Structure-based Drug Discovery

Introduction to Self-Service DNA-Encoded libraries (DELs)

Keeping Pace with Big Pharma - On A Start Up Budget

Putting AI in R&D

Managing Global Studies with Regional Partners

Faster, More Efficient Trials: Novel Trial Designs using Digital Twins

Why Australia is the World’s Leading Early Phase Destination – Rapid Start-up, No IND Required, and a Government-Backed Refund on Almost Half of all Trial Costs

The Transformation of Clinical Trial Design and Operations: A Panel Discussion on COVID-19 as a Catalyst for Decentralized Trials

AI, Digital Twins, and the Future of Clinical Research

When cell and gene therapies surge to market, how resilient will your cell sourcing infrastructure be?

The Australian Early Phase Biosimilars Clinical Trial Landscape - How Agilex Biolabs and Nucleus Network Work Together

The FDA and Covid-19: New rules for the R&D road

Novel oncology trial designs with a personalized ctDNA assay

Derisking orphan drug programs in 2020 and beyond

A Clinical Investigator’s Perspective: Novel Oncology Therapy During & Beyond the COVID Pandemic

Home Nursing Support for Clinical Trials

Running First-in-human and Vaccines Studies in Australia

How Easy is it to Move your Clinical Trials to Australia?

Utilizing the immunoSEQ Assay in Clinical Trials

The Covid-19 challenge: Keeping the supply chain intact

Endpoints Editor John Carroll's Covid - 19 webinar series

Dealmaking in a time of coronavirus

Advancing Oncology Clinical Trials in Asia-Pacific

Asia-Pacific – a Global hub for Hepatology Clinical Trials

Perspectives on Partnering Post-Pandemic

Clinical Trial Continuity in Asia-Pacific during the COVID-19 Pandemic

The Australian Advantage: De-risk your early phase trials

Rapid Deployment of Remote Trials During Containment

RWD for R&D: Examples from Immunology, Rheumatology and Other Chronic Diseases

Designing a turnkey orphan drug program

The do’s and don’ts of managing a pivotal gene therapy trial

You've got that coveted accelerated regulatory pathway. Now what?

Developing better assays for biopharma with a CRO partner

Are you really ready for your end of phase 2 meeting?

How to run a Digital Trial and reduce time in development by 50%

Improving Clinical Trial Quality with Best Practices for E-Clinical Technology

Developing a digital therapeutics trial

The Experts: Real World Endpoints

Designing Next-Gen Oncology Trials

ctDNA as a biomarker for monitoring treatment response and molecular recurrence in early-stage and metastatic cancers

How to get the most out of your Phase I biologic study

The Alzheimer's Trials of the Future